Cynata Therapeutics (ASX:CYP) has signed an agreement with Regience K.K., a regenerative medicine venture company based in Japan for an investment in Cynata of A$250,000.
This is the first part of an alliance which would entail the companies co-operating to develop and commercialise Cynata’s therapeutic mesenchymal stem cell (MSC) technology for Japan and for certain Asian countries.
If Regience proceeds it must invest an additional A$2,250,000 in new ordinary shares issued by Cynata, based on the same pricing structure and escrow as the initial investment.
This additional investment would provide Regience with an exclusive two year option to Cynata’s Cymerus technology.
The Cymerus stem cell technology provides a source of MSCs that is independent of donor limitations and provides a potential “off-the-shelf” stem cell platform for therapeutic product use, with a pharmaceutical business model and economies of scale.
The potential commercial market in Japan and neighbouring countries for the technology's therapeutic use in these markets could result in hundeds of millions of dollars the company said.
Regience K.K. develops multiple cell-based products and has seven regenerative medicine projects in a research & development pipeline.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.